ARS Pharmaceuticals (SPRY) Stock Overview
A biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 4/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for SPRY from our risk checks.
SPRY Community Fair Values
Create NarrativeSee what 51 others think this stock is worth. Follow their fair value or set your own to get alerts.
Looking to be second time lucky with a game-changing new product
Key Takeaways Unicycive has successfully completed clinical development of its lead asset, Oxylanthanum Carbonate (OLC). OLC has been designed to improve on current phosphate binders by offering better efficacy, fewer pills, and improved tolerability over alternative treatments for hyperphosphatemia chronic kidney disease patients on dialysis.Read more
ARS Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.56 |
| 52 Week High | US$18.90 |
| 52 Week Low | US$6.66 |
| Beta | 0.78 |
| 1 Month Change | -6.35% |
| 3 Month Change | -24.78% |
| 1 Year Change | -32.22% |
| 3 Year Change | 27.19% |
| 5 Year Change | n/a |
| Change since IPO | 41.25% |
Recent News & Updates
Recent updates
ARS Pharmaceuticals: Climbing Neffy Sales And Global Expansion Could Re-Rate The Stock
Feb 14ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Catapults 25% Though Its Price And Business Still Lag The Industry
Jan 10
ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) May Have Run Too Fast Too Soon With Recent 27% Price Plummet
Aug 28ARS Pharmaceuticals (NASDAQ:SPRY) May Not Be Profitable But It Seems To Be Managing Its Debt Just Fine, Anyway
Aug 15ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stock Rockets 26% As Investors Are Less Pessimistic Than Expected
Jun 30Analysts Have Just Cut Their ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Revenue Estimates By 15%
May 15
80% Coverage And Pediatric Launch Will Expand Global Markets
Rapid payer coverage expansion and pediatric market entry may enhance revenue and ease prescribing burdens with reduced authorization requirements.Revenues Not Telling The Story For ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) After Shares Rise 28%
Apr 03Downgrade: Here's How Analysts See ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Performing In The Near Term
Mar 26ARS Pharmaceuticals' Neffy Launch Could Be A Hit For Severe Allergic Reactions
Feb 06ARS Pharmaceuticals: Demand Curve Is Key Unknown
Nov 20We're Interested To See How ARS Pharmaceuticals (NASDAQ:SPRY) Uses Its Cash Hoard To Grow
Sep 13ARS Pharmaceuticals: A Decent Bet For Upside After Neffy Approval
Sep 06ARS Pharmaceuticals On Track With Neffy Despite Regulatory Hurdles
Jun 25We're Not Very Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Rate
Mar 18ARS Pharmaceuticals (NASDAQ:SPRY) Is In A Good Position To Deliver On Growth Plans
Nov 14Here's Why We're Not Too Worried About ARS Pharmaceuticals' (NASDAQ:SPRY) Cash Burn Situation
May 12Shareholder Returns
| SPRY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.8% | 0.4% | -1.6% |
| 1Y | -32.2% | 23.9% | 15.2% |
Return vs Industry: SPRY underperformed the US Biotechs industry which returned 25% over the past year.
Return vs Market: SPRY underperformed the US Market which returned 15.9% over the past year.
Price Volatility
| SPRY volatility | |
|---|---|
| SPRY Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.9% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: SPRY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SPRY's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 161 | Rich Lowenthal | ars-pharma.com |
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
ARS Pharmaceuticals, Inc. Fundamentals Summary
| SPRY fundamental statistics | |
|---|---|
| Market cap | US$784.45m |
| Earnings (TTM) | -US$171.30m |
| Revenue (TTM) | US$84.28m |
Is SPRY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SPRY income statement (TTM) | |
|---|---|
| Revenue | US$84.28m |
| Cost of Revenue | US$33.60m |
| Gross Profit | US$50.67m |
| Other Expenses | US$221.97m |
| Earnings | -US$171.30m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.73 |
| Gross Margin | 60.13% |
| Net Profit Margin | -203.25% |
| Debt/Equity Ratio | 147.5% |
How did SPRY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/03/26 07:59 |
| End of Day Share Price | 2026/03/26 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
ARS Pharmaceuticals, Inc. is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Joshua Schimmer | Cantor Fitzgerald & Co. |
| Roanna Clarissa Ruiz | Leerink Partners LLC |
| Andreas Argyrides | Oppenheimer & Co. Inc. |